Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IEV407 in advanced HR+/HER2- breast cancer
NCT07604571Phase 1Recruiting
- Sponsor
- Novartis
- Start
- May 2026
- Primary completion
- Jun 2032
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 1, randomised, open-label trial of IEV407 in breast cancer (5 arms), sponsored by Novartis. Primary endpoints: Dose-limiting toxicities at 28 days, Adverse Events and Serious Adverse Events at 2 years and 2 more. Started May 2026; status: recruiting.
02
Drugs
IEV407
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07604571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07604571.